Alesco Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$547K Sell
456
-7
-2% -$7.15K 0.01% 154
2026
Q1
$426K Buy
463
+38
+9% +$38.5K 0.01% 181
2025
Q4
$457K Sell
425
-91
-18% -$87K 0.01% 143
2025
Q3
$394K Buy
516
+110
+27% +$81.9K 0.01% 153
2025
Q2
$316K Buy
406
+75
+23% +$58.3K 0.01% 160
2025
Q1
$273K Buy
331
+25
+8% +$20.8K 0.01% 161
2024
Q4
$236K Buy
306
+36
+13% +$29.8K 0.01% 170
2024
Q3
$239K Buy
270
+2
+0.7% +$1.8K 0.01% 167
2024
Q2
$243K Buy
+268
New +$214K 0.01% 166

Other funds holding LLY

Alesco Advisors's LLY Position: Q2 2026 in Review

Alesco Advisors reduced its Eli Lilly (LLY) stake by 1.5% in Q2 2026, selling an estimated $7.15K and leaving 456 shares worth $547K. The position accounts for 0.01% of the portfolio, ranked #154.

Alesco Advisors first reported a position in LLY in Q2 2024 and has held it in 9 quarters since. 4,634 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Alesco Advisors held 456 shares of Eli Lilly worth $547K as of Q2 2026.
  • Alesco Advisors sold 7 Eli Lilly shares in Q2 2026, an estimated $7.15K.
  • Eli Lilly made up 0.01% of Alesco Advisors's portfolio in Q2 2026, its #154 holding.
  • Alesco Advisors first reported a position in Eli Lilly in Q2 2024 and has held it in 9 quarters since.
  • 4,634 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Alesco Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.